ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: August 24, 2026 , by Hayden Michael R .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director | Buy | 53,613 | $10.64 | $570.4K | 1,373,397 | |
| Montalbano John S. | Director | Buy | 10,000 | $11.03 | $110.3K | 251,000 | |
| Booth Andrew | Chief Financial Officer | Buy | 37,200 | $10.32 | $383.9K | 482,800 | |
| Hayden Michael R | Director | Buy | 46,387 | $10.37 | $481.0K | 1,319,784 | |
| Montalbano John S. | Director | Buy | 20,000 | $4.77 | $95.4K | 241,000 | |
| Booth Andrew | Chief Financial Officer | Buy | 42,600 | $3.42 | $145.7K | 195,600 | |
| Thermopylae Holdings Ltd. | 10% Owner | Buy | 38,000 | $3.44 | $130.7K | 56,134,097 | |
| Thermopylae Holdings Ltd. | 10% Owner | Buy | 177,457 | $3.27 | $580.3K | 56,096,097 | |
| Montalbano John S. | Director | Buy | 50,000 | $3.57 | $178.5K | 221,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.